After a corona vaccination with Johnson & Johnson, 100 cases of Guillain-Barré syndrome have been reported in the USA – with around 12.5 million vaccine doses administered.
Washington – In the case of a vaccination with the corona vaccine from the pharmaceutical company Johnson & Johnson, the US drug agency FDA has warned of an increased risk of “a rare nerve disease. The FDA updated its warning on Monday (07/12/2021) after dozens of cases of the so-called Guillain -Barré syndrome had been reported.
Corona vaccination warning: Setback for Johnson Johnson
According to information from informed circles, there are 100 preliminary reports of the occurrence of the neurological disease with symptoms of paralysis – with around 12.5 million J&J vaccine doses administered. In 95 cases, the patients had to be hospitalized. A person died.
There are between 3,000 and 6,000 cases of Guillain-Barré syndrome in the United States annually. The inflammatory neurological disease leads to muscle weakness and paralysis. Most patients recover. The syndrome has also been observed with some flu vaccinations.
Corona vaccine from Johnson & Johnson does not play a role in the USA
For Johnson & Johnson, the FDA’s new warning is another setback. In April, the US pharmaceutical company’s use of the corona vaccine was temporarily suspended after isolated cases of rare blood clots occurred, especially among younger women. However, authorities concluded that the benefits of vaccination clearly outweighed the risks. A major production breakdown at a plant in the US city of Baltimore also made headlines.
In the US vaccination campaign, the vaccine from Johnson & Johnson, of which only one dose is required, plays a minor role. So far, fewer than 13 million vaccine doses have been given. More than 185 million of the corona vaccine from Biontech-Pfizer and more than 135 million of the vaccine from the biotech company Moderna have already been administered. (FR / afp)
